The FDA approved the Monjuvi (tafasitamab-cxix) joint lying to treat relapse diffuse large B-cell lymphoma.

Pharmaceutical companies MorphoSys and Incyte announced today that the U.S. Food and Drug Administration (FDA) has approved a combination of Monjuvi ® (tafasitamab-cxix) to treat patients with recurrent or refractable diffuse large B-cell lymphoma (DLBCL) that are not suitable for autologous stem cell transplantation (ASCT).
Tafasitamab-cxix is a monoclonal antibody of humanized target CD19, which has been approved by the FDA.
DLBCL is the most common non-Hodgkin lymphoma in adults worldwide, characterized by a rapid increase in the number of malignant B cells in the lymph nodes, spleen, liver, bone marrow or other organs.
DLBCL is an aggressive disease, and about one-third of patients are ineffective with initial treatment.
in the United States, about 10,000 people are diagnosed each year with recurrent or refractive DLBCL.
, depending on their genetic activity, DLBL can be divided into three main subtypes: activated B-cell lymphoma (ABC-DLBCL), biofirst B cell lymphoma (GCB-DLBCL) and primary-cell lymphoma (PMBL). "The FDA approves Monjuvi's combination with Lenadoamine to help address the urgent medical needs of patients with recurrent or refractory DLBCL in the United States," said Herv? Hoppenot, CEO of
Incyte.
in Inccyte, we are committed to improving patient care."
.